linjc16/ctgov huggingface dataset:
Selective Internal Radiation Therapy (SIRT) Versus Transarterial Chemoembolisation (TACE) for the Treatment of Hepatocellular Carcinoma (HCC).

Study Overview
=================
Brief Summary
-----------------
Selective Internal Radiation Therapy is superior to Transarterial Chemoembolisation for the treatment of intermediate stage hepatocellular carcinoma.

Official Title
-----------------
Selective Internal Radiation Therapy (SIRT) Versus Transarterial Chemoembolisation (TACE) for the Treatment of Hepatocellular Carcinoma (HCC).

Conditions
-----------------
Hepatocellular Carcinoma

Intervention / Treatment
-----------------
* Procedure: DEB TACE
* Procedure: SIRT


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: ≥18 years HCC, proven by histology or according to EASL criteria Intermediate stage HCC (stage B according to BCLC) At least one measurable lesion in magnetic resonance imaging (MRI) Tumor load ≤ 50% preserved liver function (Child Pugh A and B) Exclusion Criteria: Patients feasible for curative treatment (e.g. resection or local ablation) Previous TACE or SIRT Chemotherapy during the last 4 weeks Child Pugh stage C BCLC stage D ECOG Performance Status >0 Tumor involvement >50% of the liver Extrahepatic tumor Serum Bilirubin >2.0 mg/dl; Serum Albumin 2.8 g/dl, Serum Creatinine >2 mg/dl; Leukocytes <3000/ml; Thrombocytes <50000/ml Clinically apparent ascites (ascites only in CT/MRI is no exclusion criteria) Esophageal bleeding during the last 3 months Hepatic encephalopathy Transjugular intrahepatic portosystemic shunt (TIPS) Infiltration or occlusion of the portal vein Hepatofugal blood flow in the portal vein Hepatopulmonary shunt ≥ 20% in the macroaggregated albumin scan Contraindications against angiography Gravidity

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Active Comparator: DEB TACE<br>Drug eluting Beads (DC Beads) loaded with Doxorubicin | Procedure: DEB TACE<br>* DEB TACE every 6 weeks until either no viable tumor or endpoint reached.<br>* Other names: Chemoembolization;|
| Experimental: SIRT<br>Selective Internal Radiation Therapy using Yttrium 90 loaded resin beads (Sir Spheres) | Procedure: SIRT<br>* Selective Internal Radiation Therapy once at the beginning of the study. Follow up until endpoint.<br>* Other names: Radioembolization;|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Progression-free-Survival |  | up to three years | 
| Overall-Survival |  | up to three years |
Zmax Compared to Augmentin in Sinusitis

Study Overview
=================
Brief Summary
-----------------
This study will enroll patients with Bacterial Sinusitis who will be treated with either Zmax (Azithromycin Extended Release) or Augmentin (Amoxicillin/Clavulanate). The purpose of the study is to compare early resolution of symptoms between the two treatments. Patients will report resolution of their sinusitis symptoms through a daily questionnaire. There will be two follow-up telephone interviews on days 12 and 28 to evaluate quality of life, satisfaction with therapy, and use of healthcare services.

Official Title
-----------------
A Multicenter, Randomized, Open Label Comparative Study Of Azithromycin Extended Release (ZMAX) Versus Amoxicillin/Clavulanate Potassium In Subjects With Acute Bacterial Sinusitis (ABS) In A Physician Practice Environment

Conditions
-----------------
Sinusitis

Intervention / Treatment
-----------------
* Drug: Azithromycin Extended Release
* Drug: Amoxicillin/Clavulanate


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: A clinical diagnosis of acute uncomplicated bacterial maxillary sinusitis as demonstrated by presence of the following cardinal signs and symptoms for a minimum duration of 7 days, and no longer than 30 days: Facial pain, pressure and/or tightness over one or both maxillary sinuses, and/or pain in one or both maxillary areas that worsens with movement or percussion, and Presence of one or more of the following signs: Discolored (yellow-green) nasal discharge Discolored (yellow-green) drainage in the posterior pharynx Discolored (yellow-green) discharge from the maxillary sinus orifice Two or more of the following symptoms are present: Fever, as defined by: Oral temperature: >38C or >100.4F, or Tympanic temperature: >38.5C or >101.2F Frequent coughing Nasal congestion, Post-nasal drainage. Exclusion Criteria: Treatment with any systemic antibiotic within 30 days prior to enrollment Symptoms of sinusitis lasting for longer than 30 days; Four or more episodes of acute sinusitis within the preceding 12 months;

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)


Arms and Interventions

| Intervention/Treatment |
| --- |
|Drug: Azithromycin Extended Release|nan|
|Drug: Amoxicillin/Clavulanate|nan|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Patient reported symptom resolution at day 5 |  |  | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Time to symptom resolution. |  |  |
Minimal Occlusive Pressure With Cuffed ETT: the Effect of Size on Intracuff Pressure

Study Overview
=================
Brief Summary
-----------------
The purpose of this current study is to evaluate whether the size of the endotracheal tube (ETT) that is used impacts the intracuff pressure that occurs when the airway is sealed. If there is excessive pressure in the cuff of a smaller ETT when it is inflated, there may be inherent risks associated with the use of a cuffed endotracheal tube that is less than the appropriate size. The investigators believe that the size of the tube chosen has an impact on the characteristics of the inflated cuff and hence the intracuff pressure and the sealing pressure are variable.

Official Title
-----------------
Minimal Occlusive Pressure With Cuffed ETT: the Effect of Size on Intracuff Pressure

Conditions
-----------------
Intracuff Pressure, ETT Size

Intervention / Treatment
-----------------
* Procedure: Surgery less than 60 minutes


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patients requiring intubation with an ETT for a surgical procedure. Children ages 4 to 8 years old. Surgical procedure lasting less than 60 minutes. Exclusion Criteria: Patients undergoing a surgical procedure that is anticipated to last longer than 60 minutes. Patients that are known or anticipated to have a difficult airway.

Ages Eligible for Study
-----------------
Minimum Age: 4 Years
Maximum Age: 8 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Diagnostic
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Active Comparator: Standard ETT size<br>Their tracheas will be intubated with an appropriately sized ETT using the standard formula. The cuff will be inflated to achieve a seal by the air-leak test when holding CPAP of 20 cmH2O and the intracuff pressure will be measured using a manometer. | Procedure: Surgery less than 60 minutes<br> <br> |
| Experimental: ETT one size smaller<br>Their tracheas will be intubated with an ETT that is one size smaller (instead of a 5.0 ETT, we would use a 4.0 ETT). The cuff will be inflated to achieve a seal by the air-leak test when holding CPAP of 20 cmH2O and the intracuff pressure will be measured using a manometer. | Procedure: Surgery less than 60 minutes<br> <br> |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Intracuff pressure | Our goal is to measure the intracuff pressure that is achieved when the airway is sealed with an ETT based on the formula (ETT=(age/4)+3) and compare it to the intracuff pressure when the airway is sealed with an ETT that is 1 size smaller (4.0 mm instead of 5.0 mm). | intraoperative |
Secular Trends in the Prevalence of Diabetes in India

Study Overview
=================
Brief Summary
-----------------
Series of epidemiological studies have been carried out by the research team since 1988 studying the changes in the prevalence of type 2 diabetes, prediabetes and associated risk factors. These studies have shown that the determinants to rising prevalence of diabetes vary among populations and with time. Comparative studies from the same region can help to understand the secular changes occurring in a specific population. In this proposal we intend to conduct a cross-sectional survey with varied levels of urbanisation and compare the findings with our earlier reported data to assess the degree of changes in dysglycaemic prevalences. The primary aim of the proposal is to study the secular changes and the prevalence of diabetes, prediabetes and associated cardio-metabolic risk factors with varying levels of urbanization. A multi-stage random selection method will be used. Field workers will conduct an enumeration of the individuals above 20 years of age. In each location, streets will be randomly selected to have an equal representativeness from different socio-economic strata. All eligible family members of the selected households are invited for the survey. The study outcomes will be of relevance in public health research in modeling effective national healthcare policies.

Official Title
-----------------
Secular TRends in DiabEtes in India

Conditions
-----------------
Type2 Diabetes, PreDiabetes

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Willing to participate and provide informed consent form. Exclusion Criteria: Age less than 20 years,cognitive impairment, unwilling to participate

Ages Eligible for Study
-----------------
Minimum Age: 20 Years
Maximum Age: 70 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Prevalence of type 2 diabetes | Prevalence of type 2 diabetes ,impaired fasting glucose and impaired glucose tolerance in a city, town and peri urban village in Southern India | Upto 18 months | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Secular trend in diabetes risk factors |  | Upto 18 months | 
| Prevalence of cardiovascular risk factors |  | Upto 18 months | 
| Prevalence of dysglycaemia in the young population aged ≤ 40 years |  | Upto 18 months | 
| Prevalence of age-related hypertension in these regions |  | Upto 18 months | 
| Changes in physical activity |  | Upto 18 months | 
| Quality of diabetes care |  | Upto 18 months | 
| Changes in dietary habits |  | Upto 18 months |
The Study of How Long Participants Stay in the Hospital After Receiving Apixaban for a Blood Clot in the Lung

Study Overview
=================
Brief Summary
-----------------
A study based on a chart review of participants that presented with a sudden blood clot in the lung

Official Title
-----------------
Apixaban Length-Of-Stay Pulmonary Embolism Study - Hospital Admissions (ALPHA-PE)

Conditions
-----------------
Pulmonary Embolism (PE), Pulmonary Thromboembolism

Intervention / Treatment
-----------------
* Other: Non-Interventional


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Adults participants at date of admission Primary presentation consistent with PE followed by objectively-confirmed acute PE Received anti-coagulation upon diagnosis of PE during study period and in receipt of anti-coagulation at discharge Exclusion Criteria: PE diagnosed during a hospital admission for a reason other than PE during the study period Patients receiving anticoagulation at the time of presentation Patients presenting outside the defined study period Other protocol defined inclusion/exclusion criteria could apply

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Adult with acute PE before the introduction of apixaban<br> | Other: Non-Interventional<br>* Non-Interventional<br>|
| Adult with acute PE after the introduction of apixaban<br> | Other: Non-Interventional<br>* Non-Interventional<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Compare the average length of stay in secondary care |  | 60 days | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Total length of stay, including repeat admissions |  | During the first 30 days after presentation of PE | 
| Distribution of clinical characteristics of patients admitted with a PE | Clinical characteristics will be summarized using descriptive statistics | Baseline | 
| Distribution of demographic data of patients admitted with a PE | Demographic data will be summarized using descriptive statistics | Baseline |
Clinical Outcome of Extended-depth-of-focus Trifocal Intraocualr Lens (Triumf) Implantation

Study Overview
=================
Brief Summary
-----------------
Clinical outcome of extended-depth-of-focus trifocal intraocualr lens (Triumf) implantation

Official Title
-----------------
Clinical Outcome of Extended-depth-of-focus Trifocal Intraocualr Lens (Triumf) Implantation

Conditions
-----------------
Presbyopia

Intervention / Treatment
-----------------
* Device: Triumf


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Adult at the age of 21 or older at the time of the pre-operative examination and willing to have surgery on their 2nd eye within 7-28 days of their 1st eye Age-related cataract A patient with preoperative corneal astigmatism from IOL Master less than 1 diopters A patient want presbyopia correction at the same time as cataract surgery A patient has the visual potential of 20/25 or better in each eye after cataract removal and IOL implantation Written informed consent to surgery and participation in the study Exclusion Criteria: Those with other diseases that can affect capsule stability such as pseudoexoliation syndrome, glaucoma, traumatic cataract Pregnant woman and lactating woman A patient with history of ocular trauma or ocular surgery (Intraocular surgery, refractive surgery, ocular surface surgery) in either eye A patient with evidence of keratoconus or significant irregular astigmatism on pre-operative topography in either eye If expectations for presbyopia correction are too high Those who are not able to read and understand the informed consent (illiterate or foreigners)

Ages Eligible for Study
-----------------
Minimum Age: 21 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Other: Triumf<br>Subjects who have cataract surgery with Triumf IOL | Device: Triumf<br>* Triumf is intraocular lens which offers multifocal vision by extended depth of focus and diffractive optics.<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Uncorrected distant visual acuity | Visual acuity at distant with bare eyes | 3 months | 
| Uncorrected near visual acuity | Visual acuity at near with bare eyes | 3 months | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Contrast sensitivity | Ability to recognize figure or letter at different contrast environment | 3 months | 
| Quality of Vision | Degree of various symptoms associated with vision | 3 months | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Depth and focus
Assessment of NAPS Performance.

Study Overview
=================
Brief Summary
-----------------
To measure competencies in propofol sedation for endoscopic procedures (NAPS)through development, test and validation of a reliable assessment tool in a simulator setting. Hypothesis: That the tool will demonstrate content and construct validity, ie. enable reliable measuring of necessary competencies of different levels in a reproducible way.

Official Title
-----------------
A Reliable and Valid Assessment of Nurse Administered Propofol Sedation (NAPS) Performance.

Conditions
-----------------
Competence in Propofol Sedation for Endoscopy

Intervention / Treatment
-----------------
* Behavioral: unexperienced endoscopy nurses
* Behavioral: Experienced endoscopy nurses


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: eligible nurses, written informed consent. Exclusion Criteria: Prior anesthesia or ICU experience

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 90 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Nurse Trainees<br>unexperienced endoscopy nurses | Behavioral: unexperienced endoscopy nurses<br> <br> |
| Nurse Experts<br>Educated endoscopy Nurses | Behavioral: Experienced endoscopy nurses<br> <br> |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Assessed sedation performance score | A Total of 12 Global Rating Scores and 2 checklist scores on hands on performance in a simulation setting and a theoretical Multiple Choice questionnaire. The performance score is decided by independent raters who review performances on video. | 6 months | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Propofol, Sedation, Endoscopy, nonanesthesiologist
Cultural Differences in Treatment Preferences and Perceptions of Acne

Study Overview
=================
Brief Summary
-----------------
This study will use a survey to examine relationships between culture, race, and ethnicity with treatment preferences and perceptions for acne vulgaris.

Detailed Description
-----------------
The purpose of this study is to determine how explanatory models, perceptions, and treatment preferences of acne vulgaris vary across different cultures and racial and ethnic backgrounds. This study will also use Willingness to Pay to investigate differences in treatment valuation. Clarifying these differences will better inform patient counseling and treatment adherence by improving the quality of shared decision making.

Official Title
-----------------
Cultural, Racial, and Ethnic Differences in Treatment Preferences and Perceptions of Acne Vulgaris

Conditions
-----------------
Acne Vulgaris

Intervention / Treatment
-----------------
* Other: Survey


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Subjects must have acne vulgaris, be at least 18 years of age, and must be able to complete a survey published in English. Exclusion Criteria: -

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| ResearchMatch Group<br> | Other: Survey<br>* 31 question survey with questions regarding non-identifying demographic information such as age and gender. This survey also contains questions about acne treatment preferences, racial/ethnic background, and cultural identity in addition to a few Willingness to Pay questions.<br>|
| Northwestern Center for Ethnic Skin Group<br> | Other: Survey<br>* 31 question survey with questions regarding non-identifying demographic information such as age and gender. This survey also contains questions about acne treatment preferences, racial/ethnic background, and cultural identity in addition to a few Willingness to Pay questions.<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Willingness to Pay | percentage of income individual is willing to pay to use a treatment that improves his or her acne | 15 minutes | 
| Preferred and Least Preferred Treatments | ranked list of treatments for acne that individuals prefer and don't prefer using (ie. masks/facials, isotretinoin, etc) and reasons for why individuals prefer or don't prefer using that treatment (ie. cost, safety, efficacy, etc.) | 15 minutes |